Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2025-03-17 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Imfinzi approved in EU for limited-stage SCLC
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 9025A' and is dated 17 March 2025. It details a significant regulatory/medical event: the EU approval of AstraZeneca's drug Imfinzi for limited-stage small cell lung cancer, citing Phase III trial results (ADRIATIC). The text concludes with standard RNS disclaimers and contact information, including the line: 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure is characteristic of a general regulatory announcement disseminated via the RNS system, which serves as a primary information provider for the London Stock Exchange. Since the content is a specific announcement (drug approval based on trial data) and not a full annual report (10-K), earnings release (ER), or a formal presentation (IP), the most appropriate classification is the general regulatory filing category, RNS, as it is explicitly identified as an RNS release.
2025-03-17 English
AstraZeneca to acquire EsoBiotec
M&A Activity Classification · 1% confidence The document is identified by the header 'RNS Number : 9023A' and concludes with information about RNS, the news service of the London Stock Exchange. The content details a definitive agreement for AstraZeneca to acquire EsoBiotec, including financial considerations and expected closing dates. This is a corporate announcement regarding a significant business transaction (M&A activity). While it describes a transaction, the format and source (RNS) strongly suggest it is a regulatory disclosure. Since 'M&A Activity' (TAR) is a specific category for merger proposals or takeover bids, and this is a definitive agreement for an acquisition, TAR is the most appropriate classification. It is not a general regulatory filing (RNS) because it fits a more specific category.
2025-03-17 English
HOLDING(S) IN COMPANY
Foreign Filer Report
2025-03-12 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and is filed via 'RNS Number'. This form is used to report changes in major shareholdings (crossing thresholds) by individuals or entities, which falls under insider/significant shareholder reporting. The definition for 'Director's Dealing' (DIRS) covers personal share transactions by directors, but this specific form (TR-1) is the standard regulatory notification for any person crossing a major holding threshold (often 3% or 5%). Since the document reports an 'acquisition or disposal of voting rights' resulting in a holding of 5.000629%, it is a notification of a change in major shareholding. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the most appropriate fit for reporting changes in significant ownership levels crossing thresholds, as opposed to DIRS (which is usually for directors' personal trades) or RNS (which is a general fallback).
2025-03-12 English
Director's Dealing 2025
Director's Dealing Classification · 1% confidence The document details a change in shareholding ('Innehavare') for AstraZeneca PLC, specifically reporting the number of shares and voting rights before and after a transaction on 2025-03-10. The transaction reason is listed as 'Köp' (Buy). This structure, focusing on insider/significant shareholder transactions and crossing ownership thresholds (5%), is characteristic of a Director's Dealing report or a Major Shareholding Notification. Since the document explicitly details the transaction by a major holder ('The Capital Group Companies, Inc.') and reports the resulting percentage ownership crossing a threshold (5%), it aligns best with the definition of a Major Shareholding Notification (MRQ) or a Director's Dealing (DIRS). Given that the holder is a large investment management group and the filing reports the change in total holding percentage, 'Major Shareholding Notification' (MRQ) is the most precise fit, as it tracks significant ownership changes, which often encompasses institutional holders crossing thresholds. It is not a director's personal trade (DIRS), nor is it a general regulatory announcement (RNS) or a report publication announcement (RPA), as it contains substantive data about ownership change.
2025-03-12 Swedish
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2025-03-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.